Liberal Transfusion Strategy in Elderly Patients — LIBERAL  

Surgery Clinical Trial

Official title: Liberal Transfusion Strategy to Prevent Mortality and Anaemia-associated, Ischaemic Events in Elderly Non-cardiac Surgical Patients

Status Recruiting

Clinical Trial Summary

In this prospective, multicentre, open, randomised, controlled clinical trial elderly patients (≥ 70 years) undergoing intermediate- or high-risk non-cardiac surgery will be randomised either to a liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)) or restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l). Primary efficacy endpoint: is a composite of death from any cause and anaemia-associated, ischaemic events (defined as acute myocardial infarction, acute ischaemic stroke, acute kidney injury stage III, acute mesenteric ischaemia, acute peripheral vascular ischaemia) within 90 days after surgery.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Anemia
• Surgery
• Transfusion-dependent Anemia

• NCT number: NCT03369210
• Study type: Interventional
• Source: Johann Wolfgang Goethe University Hospital
• Contact: Patrick Meybohm, MD
• Phone: 004993120130001
• Email: meybohm_p@ukw.de
• Status: Recruiting
• Phase: Phase 3
• Start date: December 4, 2017
• Completion date: December 31, 2025